Skip to main content

Table 3 Risk assessment of clinical parameters for advanced fibrosis

From: Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)

Variable Fibrosis 0-2 (n = 88) Fibrosis 3-4 (n = 15) p OR 95% CI
Age ≥ 50 years 39 (44.3%) 11 (73.3%) 0.038 3.455 1.021-11.694
BMI ≥ 28 58 (65.9%) 10 (66.7%) 0.954 1.034 0.324-3.302
DMt2 14 (15.9%) 5 (33.3%) 0.109 2.643 0.783-8.916
HOMA (<1.8) 32(46.4%) 7(70%) 0.193 2.698 0.644-11.306
AST/ALT ≥ 0,8 17 (19.3%) 13 (86.7%) p < 0.001 27.147 5.592-131.974